Market Moves
Mobia Medical's $150 million stroke-VNS IPO falls 22% in week one as first major neurotech listing of 2026 underperforms
Mobia Medical, the company behind the only FDA-approved implanted vagus nerve stimulator for chronic stroke recovery, priced its $150 million IPO at $15 on 7 May 2026 and closed week one at $11.75. The print resets implied exit math for the pre-IPO bioelectronic-medicine cohort preparing 2026-27 listings.